

**Applicant Initiated Interview Request Form**Application No.: 10/535,351First Named Applicant: Samuel R. DenmeadeExaminer: Maury AudetArt Unit: 1654Status of Application: pending**Tentative Participants:**(1) Maury Audet(2) Thomas P. Thrash

(3) \_\_\_\_\_

(4) \_\_\_\_\_

Proposed Date of Interview: August 19, 2010

Proposed Time: \_\_\_\_\_ (AM/PM)

**Type of Interview Requested:**(1) ☒ Telephonic(2) ☐ Personal(3) ☐ Video ConferenceExhibit To Be Shown or Demonstrated: ☐ YES☒ NO

If yes, provide brief description: \_\_\_\_\_

**Issues To Be Discussed**

Issues (Rej., Obj., etc)	Claims/ Fig. #s	Prior Art	Discussed	Agreed	Not Agreed
(1) <u>N/A</u>	_____	_____	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(2) _____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(3) _____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(4) _____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Continuation Sheet Attached☐ Proposed Amendment or Arguments Attached**Brief Description of Arguments to be Presented:**


Applicants' representative and Examiner discussed status of final rejection and previously proposed

Examiner's amendment. The amendment to claim 21 shall read "wherein the therapeutically active drug is directly linked to the peptide C-terminal carboxylic acid". The Examiner is awaiting an updated search in view

of the amendment and is prepared to withdraw the final rejection and issue a notice of allowance if no new art becomes of record. The Examiner acknowledged the acceptance of the terminal disclaimer over 11/725,135.

An interview was conducted on the above-identified application on August 19, 2010.**NOTE:** This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP § 713.01).

This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as possible.



Applicant/Applicant's Representative Signature

Thomas P. Thrash

Typed/Printed Name of Applicant or Representative

64,805

Registration Number, if applicable

Examiner/SPE Signature

This collection of information is required by 37 CFR 1.133. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 21 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.